Healthcare provider profile · identity verified

Mary Ellen Ritchie, M.D.

Family Practice · SILVER SPRING, MD · NPI 1255397741

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	560	158
Levothyroxine Sodium	Levothyroxine Sodium	451	126
Amlodipine Besylate	Amlodipine Besylate	347	98
Losartan Potassium	Losartan Potassium	330	94
Rosuvastatin Calcium	Rosuvastatin Calcium	278	83
Lisinopril	Lisinopril	233	72
Pantoprazole Sodium	Pantoprazole Sodium	184	61
Hydrochlorothiazide	Hydrochlorothiazide	182	55
Ozempic	Semaglutide	179	26
Gabapentin	Gabapentin	174	56
Famotidine	Famotidine	166	53
Metoprolol Succinate	Metoprolol Succinate	162	51
Omeprazole	Omeprazole	159	53
Escitalopram Oxalate	Escitalopram Oxalate	158	43
Albuterol Sulfate Hfa	Albuterol Sulfate	145	52
Metformin Hcl	Metformin Hcl	130	40
Sertraline Hcl	Sertraline Hcl	127	37
Duloxetine Hcl	Duloxetine Hcl	126	35
Simvastatin	Simvastatin	113	31
Synthroid	Levothyroxine Sodium	109	27
Alprazolam	Alprazolam	91	32
Jardiance	Empagliflozin	87	20
Celecoxib	Celecoxib	85	18
Bupropion Xl	Bupropion Hcl	81	25
Trazodone Hcl	Trazodone Hcl	81	24
Zolpidem Tartrate	Zolpidem Tartrate	80	18
Tramadol Hcl	Tramadol Hcl	72	30
Tamsulosin Hcl	Tamsulosin Hcl	71	24
Pravastatin Sodium	Pravastatin Sodium	70	23
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	68	19
Allopurinol	Allopurinol	67	16
Fluticasone Propionate	Fluticasone Propionate	66	28
Metformin Hcl Er	Metformin Hcl	63	20
Lorazepam	Lorazepam	59	14
Furosemide	Furosemide	58	26
Prednisone	Prednisone	57	47
Atenolol	Atenolol	54	14
Fluoxetine Hcl	Fluoxetine Hcl	52	18
Clopidogrel	Clopidogrel Bisulfate	51	17
Ezetimibe	Ezetimibe	51	21
Metoprolol Tartrate	Metoprolol Tartrate	51	15
Meloxicam	Meloxicam	49	17
Spironolactone	Spironolactone	49	15
Esomeprazole Magnesium	Esomeprazole Magnesium	48	17
Pregabalin	Pregabalin	48	11
Eliquis	Apixaban	46	14
Finasteride	Finasteride	45	12
Triamcinolone Acetonide	Triamcinolone Acetonide	45	20
Estradiol	Estradiol	42	20
Montelukast Sodium	Montelukast Sodium	42	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	39	suppressed
Aripiprazole	Aripiprazole	38	suppressed
Clonazepam	Clonazepam	38	suppressed
Ibandronate Sodium	Ibandronate Sodium	38	13
Olmesartan Medoxomil	Olmesartan Medoxomil	37	12
Quetiapine Fumarate	Quetiapine Fumarate	37	suppressed
Mounjaro	Tirzepatide	36	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	34	11
Azithromycin	Azithromycin	33	25
Breo Ellipta	Fluticasone/Vilanterol	33	suppressed
Mirtazapine	Mirtazapine	33	16
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	32	suppressed
Farxiga	Dapagliflozin Propanediol	32	suppressed
Glimepiride	Glimepiride	32	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	32	14
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	29	13
Hydralazine Hcl	Hydralazine Hcl	29	12
Carvedilol	Carvedilol	28	suppressed
Ibuprofen	Ibuprofen	27	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	27	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	27	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	27	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	26	24
Potassium Chloride	Potassium Chloride	26	11
Alendronate Sodium	Alendronate Sodium	25	suppressed
Baclofen	Baclofen	22	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	22	20
Colestipol Hcl	Colestipol Hcl	21	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	21	suppressed
Propranolol Hcl Er	Propranolol Hcl	21	suppressed
Citalopram Hbr	Citalopram Hydrobromide	20	suppressed
Amoxicillin	Amoxicillin	19	12
Buspirone Hcl	Buspirone Hcl	19	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	19	15
Clonidine Hcl	Clonidine Hcl	18	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	18	suppressed
Topiramate	Topiramate	18	suppressed
Diclofenac Sodium	Diclofenac Sodium	17	suppressed
Raloxifene Hcl	Raloxifene Hcl	17	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	17	suppressed
Valsartan	Valsartan	17	suppressed
Eszopiclone	Eszopiclone	16	suppressed
Lansoprazole	Lansoprazole	16	suppressed
Symbicort	Budesonide/Formoterol Fumarate	15	suppressed
Glipizide	Glipizide	14	suppressed
Glipizide Er	Glipizide	14	suppressed
Januvia	Sitagliptin Phosphate	14	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	14	14
Testosterone	Testosterone	14	suppressed
Tresiba Flextouch U-100	Insulin Degludec	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	13
Oxycodone Hcl	Oxycodone Hcl	13	suppressed
Rybelsus	Semaglutide	13	suppressed
Advair Diskus	Fluticasone Propion/Salmeterol	12	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Humalog Kwikpen U-100	Insulin Lispro	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Premarin	Estrogens, Conjugated	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	11	suppressed
Cefuroxime	Cefuroxime Axetil	11	11
Fluconazole	Fluconazole	11	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	11	suppressed
Levofloxacin	Levofloxacin	11	11
Telmisartan	Telmisartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error